Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Net Margin (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Net Margin data on record, last reported at 247.29% in Q4 2025.

  • For Q4 2025, Net Margin fell 1566.0% year-over-year to 247.29%; the TTM value through Dec 2025 reached 170.07%, down 645.0%, while the annual FY2025 figure was 165.14%, 180.0% up from the prior year.
  • Net Margin reached 247.29% in Q4 2025 per INM's latest filing, down from 154.17% in the prior quarter.
  • Across five years, Net Margin topped out at 14.56% in Q2 2023 and bottomed at 1615.6% in Q4 2021.
  • Average Net Margin over 5 years is 457.91%, with a median of 193.09% recorded in 2023.
  • Peak YoY movement for Net Margin: soared 151431bps in 2023, then tumbled -13590bps in 2024.
  • A 5-year view of Net Margin shows it stood at 1615.6% in 2021, then surged by 72bps to 446.61% in 2022, then soared by 73bps to 119.19% in 2023, then plummeted by -94bps to 231.63% in 2024, then decreased by -7bps to 247.29% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 247.29% in Q4 2025, 154.17% in Q3 2025, and 137.07% in Q2 2025.